首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1624417

2024 年至 2031 年帕金森氏症治療市場（依病患照護環境、通路、藥物類別及地區劃分）

Parkinson's Disease Treatment Market By Patient Care Setting, By Distribution Channel, By Drug Class, And Region for 2024-2031

出版日期: 2024年09月17日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

帕金森氏症治療市場評估，2024-2031 年

這種疾病在老年人中更為常見，全球人口正在老化。隨著人口老化，預計帕金森氏症患者的數量將會增加。隨著越來越多的人意識到帕金森氏症，早期診斷變得越來越重要。預計2023年市場規模將超過52億美元，2031年將達到99.1億美元的估值。改善帕金森氏症症狀的新藥和新療法的研發正在取得進展。政府對帕金森氏症研究的資助正在增加，這將促進新療法的開發。預計 2024 年至 2031 年期間市場複合年增長率為 8.4%。帕金森氏症治療市場：定義/概述帕金森氏症是一種導致行走困難的慢性神經系統疾病。影響包括手部震顫，心搏過緩，姿勢不穩，以及肌肉和身體部位運動僵硬。其他症狀包括心境惡劣、吞嚥困難、便秘、構音障礙、情緒變化、排尿問題、睡眠問題和皮膚問題。患者的活動和控制肌肉的能力也會受到影響。運動和非運動因素都會發揮作用。

未來幾年，由於帕金森氏症的流行和人口老化，帕金森氏症治療市場預計將擴大。政府對研究的支持以及對症多巴胺替代療法左旋多巴的日益普及，也可能推動未來幾年該產業的發展。此外，隨著研究活動從帕金森氏症的症狀治療轉向疾病改良療法，未來幾年將為帕金森氏症治療領域的新發展提供充足的機會。存在一些可能阻礙市場擴大的限制和困難。替代藥物的可用性可能會對市場造成限制。

帕金森氏症患者病率的上升以及老齡化人口的擴大如何促進帕金森氏症治療市場的成長？

隨著世界人口老化速度不斷加快，帕金森氏症的盛行率也不斷增加。這種神經退化性疾病的特徵是運動控制逐漸喪失，並且通常隨著年齡的增長而惡化。儘管其實際原因尚不清楚，但老化似乎在其發展中起著關鍵作用。人口老化趨勢尤為明顯，65歲以上人口數量大幅增加。這個年齡層的人特別容易罹患帕金森氏症，而老化是罹患這種疾病的最大風險因素之一。

醫學知識的進步，加上公眾意識的提高，使得帕金森氏症的診斷更加及時和準確。這種早期檢測可以及時介入和實施適當的治療方案，可能減緩疾病進展並改善患者的治療效果。帕金森氏症的持續研究和開發工作正在產生有希望的成果，包括新藥、新療法，甚至外科手術的發現。這些突破性的治療為患者帶來了緩解症狀和提高生活品質的希望。

世界各國政府越來越認識到帕金森氏症的社會經濟成本，並為研究工作提供更多支持。這樣的資金支持促成了突破性的發現並加速了新療法的發展。儘管帕金森氏症通常只關注運動功能障礙，但治療非運動症狀的重要性越來越受到人們的認可。認知障礙、睡眠障礙和疼痛都是影響患者整體生活品質的重要因素。因此，現代治療技術專注於治療這些因素，以改善受影響個體的生活品質。

同時，新興國家的醫療保健支出正在增加，對帕金森氏症的認識也在增強。這個蓬勃發展的行業為以前處於弱勢的群體提供了擴大治療選擇和醫療知識的機會。此外，技術發展正在極大地改變帕金森氏症的治療。遠距醫療平台、穿戴式監測設備和人工智慧診斷工具提供了遠距護理、追蹤疾病發展和根據特定患者需求個人化治療方法的新方法。這些技術有可能改變帕金森氏症的管理，使患者和醫療保健提供者都更加方便和有效率。

目前帕金森氏症治療費用高昂且療效有限，如何阻礙帕金森氏症治療市場的成長？

帕金森氏症治療的經濟負擔很重，可能會給患者帶來問題，特別是在醫療預算有限或完全缺乏保險覆蓋的地區。長期維持治療通常需要藥物和治療費用，這可能會使個人和家庭陷入經濟困難，並導致獲得醫療服務的機會不公平。目前的藥物療法可以緩解症狀，但不能解決導致帕金森氏症的根本神經過程。這些限制凸顯了對藥物的需求，這種藥物不僅可以治療症狀，還可以減緩或阻止疾病進展。開發這樣的藥物不僅需要新的治療技術，還需要更深入地瞭解疾病的原因。

雖然一些帕金森氏症藥物可以有效抑制症狀，但它們會引起運動障礙等不良副作用，這會對患者的生活品質產生重大影響。這些副作用可能會使患者不願意堅持治療方案，因此，尋找耐受性更好的藥物的重要性就凸顯出來了。缺乏可靠的診斷工具可能會阻礙帕金森氏症的早期發現，從而延遲幹預並阻礙最佳治療效果。能夠檢測生物標記和細微疾病症狀的創新診斷技術對於幫助及時診斷和介入、改善患者預後至關重要。

儘管進行了大量研究，帕金森氏症的確切病因仍然未知。這種缺乏理解的情況阻礙了針對潛在病理機制的疾病改良藥物的開發。更好地瞭解疾病機制對於確定新的治療目標和開發更有效的治療方法至關重要。接受過帕金森氏症管理培訓的神經病學家和專科醫務人員的短缺加劇了獲得醫療服務的不平等，尤其是在貧困的農村地區。透過培訓和遠距醫療平台解決人力短缺問題可以幫助患者。

地理位置、社會經濟水平和保險覆蓋範圍都會造成獲得優質帕金森氏症治療的機會差異。消除這些差異的努力包括改善醫療保健基礎設施、啟動外展計劃以及爭取讓所有帕金森氏症患者平等接受治療的政策。藥物開發和審批過程受到嚴格的監管標準，因此將新藥推向市場的時間很長且昂貴。簡化監管管道、鼓勵利害關係人合作、激發創新，都將有助於更快獲得新藥，使等待更有效治療的患者受益。

The disease is more common among older adults, and the global population is aging. As the population ages, the number of people with Parkinson's disease is expected to increase. More people are becoming aware of Parkinson's disease, and there is a growing emphasis on early diagnosis. The growth of market size to surpass USD 5.2 Billion in 2023, to reach a valuation of USD 9.91 Billion by 2031. New medications and therapies are being developed that can help to improve the symptoms of Parkinson's disease. There is increasing government funding for research into Parkinson's disease, which is leading to the development of new treatments. The market is to grow at a CAGR of 8.4% from 2024 to 2031. Parkinson's Disease Treatment Market: Definition/ Overview Parkinson's disease is a chronic neurological illness that makes it difficult to walk. The effects include hand tremors, bradykinesia, postural instability, and rigidity in muscle and body component movements. Other symptoms of this condition include dysthymia, dysphagia, constipation, dysarthria, emotional changes, urine problems, sleep abnormalities, and skin problems. The patient's ability to move and regulate their muscles is also impacted. Both motor and non-motor factors affect it.

Over the upcoming years, the Parkinson's Condition Treatment Market is anticipated to rise due to the prevalence of the disease and the aging population. Government support for research and widespread L-Dopa use, a symptomatic dopamine replacement therapy & nigrostriatal system, are further factors that have likely grown the industry in the ensuing years. Additionally, in the future years, the Parkinson's disease treatment sector has access to rich new development opportunities as research activities transition from symptomatic treatment to Parkinson's disorder modifying treatment. Some limitations and difficulties may prevent the market from expanding. The availability of alternatives is anticipated to probably serve as a market restraint.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How is the Rising Prevalence of Parkinson's Disease Alongside the Expanding Geriatric Population Contributing to the Growth of the Parkinson's Disease Treatment Market?

As the global population ages at an unprecedented rate, the prevalence of Parkinson's disease rises. This neurodegenerative condition, which is marked by progressive loss of motor control, is increasingly being related to characteristics that worsen with age. While the actual reason remains unknown, the aging process appears to play an important part in its development. The demographic change toward an older population is especially striking, with a significant increase in people aged 65 and up. This age group is especially prone to Parkinson's disease, as age is one of the most major risk factors for its beginning.

Advances in medical knowledge, combined with increased public awareness, have resulted in more timely and accurate Parkinson's disease diagnosis. This early discovery enables rapid intervention and the implementation of appropriate treatment regimens, perhaps slowing the progression of the disease and improving patient outcomes. The ongoing research and development efforts in Parkinson's disease are producing encouraging results, with the discovery of novel drugs, therapies, and even surgical interventions. These breakthrough therapy approaches provide patients hope for better symptom control and a higher quality of life.

Governments throughout the world are increasingly acknowledging the socioeconomic cost posed by Parkinson's disease and devoting more support to research activities. This financial support enables groundbreaking discoveries and promotes the development of novel treatment options. While Parkinson's disease has generally been regarded solely through the lens of motor dysfunction, there is an increasing recognition of the relevance of treating its non-motor manifestations. Cognitive impairment, sleep difficulties, and pain are all key factors influencing patients' overall well-being. As a result, modern treatment techniques focus more on treating these components of the condition to improve the quality of life for those affected.

In parallel, emerging economies are seeing an increase in healthcare spending and greater awareness of Parkinson's disease. This booming industry provides chances for expanding treatment options and disseminating medical knowledge to previously disadvantaged communities. Furthermore, technological developments are transforming Parkinson's disease treatment. Telemedicine platforms, wearable monitoring devices, and AI-powered diagnostic tools provide novel ways to give care remotely, track illness development, and personalize treatment approaches to particular patient needs. These technologies have the potential to change Parkinson's disease management by making it more convenient and efficient for both patients and healthcare providers.

How does the High Cost Associated with Treatments and the Limited Efficacy of Current Therapies for Parkinson's Disease Serve as Barriers to the Growth of the Parkinson's Disease Treatment Market?

The financial burden associated with Parkinson's disease therapy can be significant, providing issues for patients, particularly in regions with limited healthcare budgets or those without complete insurance coverage. Medication and therapy costs, which are frequently necessary for long-term maintenance, can put individuals and families under financial duress, potentially leading to inequities in access to care. Although current medications relieve symptoms, they do not address the underlying neuronal processes that cause Parkinson's disease. This constraint emphasizes the critical need for medicines that not only treat symptoms but also delay or stop disease progression. Developing such medicines necessitates a more in-depth understanding of illness causes as well as novel therapeutic techniques.

While some Parkinson's disease treatments are effective in managing symptoms, they can cause unpleasant effects such as dyskinesia, which has a substantial influence on patients' quality of life. These adverse effects may discourage patients from following treatment plans, emphasizing the significance of finding drugs with better tolerability profiles. The lack of reliable diagnostic tools hinders early detection of Parkinson's disease, delaying intervention and possibly hampering optimal treatment outcomes. Innovative diagnostic techniques capable of detecting biomarkers or subtle illness symptoms are critical for aiding timely diagnosis and intervention, thereby improving patient outcomes.

Despite substantial research, the exact cause of Parkinson's disease remains unknown. This lack of understanding impedes the development of disease-modifying medicines that address the underlying pathological mechanisms. Increasing our understanding of disease mechanisms is critical for identifying new therapeutic targets and developing more effective treatment options. A lack of neurologists and specialist healthcare providers educated in Parkinson's disease management exacerbates inequities in access to care, particularly in impoverished rural areas. Addressing the manpower deficit through training efforts and telemedicine platforms can help patients

Geographic location, socioeconomic level, and insurance coverage all contribute to disparities in access to high-quality Parkinson's disease treatment. Efforts to eliminate these disparities include improving healthcare infrastructure, launching outreach programs, and campaigning for policies that encourage equitable access to care for all Parkinson's patients. The strict regulatory criteria that govern drug development and approval processes contribute to long durations and expensive costs when bringing new therapies to market. Streamlining regulatory channels, encouraging stakeholder collaboration, and promoting innovation can all help to accelerate the availability of new medications, which benefits patients who are waiting for more effective treatment alternatives.

Category-Wise Acumens

How do Increased Patient Visits to Hospitals and the Specialized Expertise within the Hospital Pharmacies Segment Contribute to Driving Growth in the Parkinson's Disease Treatment Market?

The Hospital Pharmacies segment is showing substantial growth in the Parkinson's Disease Treatment Market and is expected to continue its growth throughout the forecast period. Because Parkinson's disease is a degenerative condition that generally necessitates long-term management and periodic adjustments to medication regimens, patients regularly visit hospitals to meet with neurologists or movement disorder experts. Hospital pharmacies, which are conveniently placed within healthcare facilities, have become the major option for people to fill prescriptions and obtain pharmaceuticals prescribed by their healthcare professionals.

Hospital pharmacies frequently hire pharmacists with specialized understanding in neurology and Parkinson's disease care. These specialists play an important role in assuring proper pharmaceutical selection, dose optimization, and patient education on treatment adherence and potential side effects. Their experience improves the quality of care for those with Parkinson's disease. Hospital pharmacies provide a wide range of Parkinson's disease treatments, such as levodopa-carbidopa formulations, dopamine agonists, MAO-B inhibitors, and anticholinergic drugs. This extensive range enables healthcare practitioners to personalize treatment regimens to specific patients' needs, improving symptom control while reducing side effects.

Certain Parkinson's disease drugs, such as levodopa-carbidopa intestinal gel (LCIG) and apomorphine infusion therapy, necessitate particular formulations and administration methods. Hospital pharmacies are equipped to combine and dispense these pharmaceuticals, allowing patients to get advanced treatment choices that may not be available in retail or community pharmacies. Hospitals frequently use a multidisciplinary approach to Parkinson's disease management that includes neurologists, movement disorder experts, nurses, pharmacists, and other healthcare professionals. This collaborative care strategy enables a thorough evaluation, personalised therapy planning, and continuing monitoring of patients' therapeutic responses and illness progression. Hospital pharmacies play an important role in this framework by promoting communication and collaboration among various parts of the healthcare team. In addition to drug distribution, hospital pharmacists may provide ancillary services such as medication treatment management, medication reconciliation, and adherence counseling. These services improve patient safety, treatment adherence, and clinical results for those living with Parkinson's disease.

How do the Effectiveness in Symptom Management and wide Acceptance, along with the Long-Standing Use of the Carbidopa/Levodopa Segment, Contribute to Driving the Growth of the Parkinson's Disease Treatment Market?

The Carbidopa/Levodopa segment is significantly leading in the Parkinson's Disease Treatment Market. Carbidopa/levodopa combination therapy is regarded as the gold standard for the treatment of Parkinson's disease symptoms, specifically motor fluctuations and dyskinesia. Levodopa, a precursor of dopamine, passes the blood-brain barrier and converts to dopamine, restoring the brain's low dopamine levels. Carbidopa improves the efficacy of levodopa by reducing its peripheral metabolism, enabling more levodopa to enter the brain. Carbidopa/levodopa is a key component of Parkinson's disease treatment due to its efficacy in symptom control.

Carbidopa/levodopa has been used for decades and is well-known as a first-line treatment for Parkinson's disease. Its efficacy and safety profile have been thoroughly researched and validated in clinical trials and real-world clinical settings. Healthcare practitioners are confident in prescribing carbidopa/levodopa, which contributes to its widespread adoption and ongoing use in clinical practice. Carbidopa/levodopa is available in a variety of dosage forms, including immediate-release tablets, extended-release formulations, orally disintegrating tablets, and orally disintegrating films. This varied spectrum of formulations enables healthcare practitioners to adjust treatment regimens to individual patients' needs, improving symptom control while avoiding undesirable effects like motor fluctuations and dyskinesia.

Carbidopa/levodopa can be taken alone or in conjunction with other drugs, such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors, to produce the best symptom management results. Combination therapy tactics try to target many elements of Parkinson's disease pathology, and may be especially useful in treating motor fluctuations and dyskinesia caused by long-term levodopa administration.

Carbidopa/levodopa medication helps many Parkinson's patients improve their symptoms and overall quality of life. Its effectiveness in treating motor symptoms such as tremor, stiffness, and bradykinesia can result in high patient satisfaction and adherence to treatment regimens. Patient preference for carbidopa/levodopa therapy, combined with its low side effect profile, contributes to its sustained success in the Parkinson's Disease Treatment Market. Overall, the significant growth shown in the Carbidopa/Levodopa category indicates the medication's critical role in effectively controlling Parkinson's disease symptoms and enhancing patients' quality of life. Its lengthy history of usage, established efficacy, numerous formulation possibilities, and patient acceptance all contribute to its continued use in Parkinson's disease treatment regimens.

Parkinson's Disease Treatment

Market Report Methodology

Country/Region-wise Acumens

How does the Advanced Healthcare Infrastructure and Robust Research and Development in North America Influence the Demand for Treatments in the Parkinson's Disease Treatment Market?

North America is estimated to dominate the parkinson's disease treatment market during the forecast period. The Asia-Pacific area is undergoing a demographic change marked by a rapidly aging population. With rising life expectancy and changing lifestyle habits, the prevalence of age-related neurological illnesses like Parkinson's disease is increasing, creating a demand for effective treatment alternatives.

Economic development and increased disposable incomes in Asia Pacific countries are driving up healthcare spending. Increased investment in healthcare infrastructure, research, and access to breakthrough therapies helps to grow the Parkinson's Disease Treatment Market in this region. Emerging economies in Asia Pacific, including China, India, and South Korea, offer considerable growth potential for pharmaceutical businesses and healthcare providers. These countries are seeing fast urbanization, growing middle-class populations, and increased knowledge of neurological illnesses, which is driving demand for Parkinson's disease therapies.

Governments in Asia Pacific are prioritizing healthcare reform and investing in disease management programs. Public health campaigns, drug subsidies, and attempts to increase healthcare access all help to drive the Parkinson's Disease Treatment Market forward by increasing patient access to treatment alternatives. North America is home to several leading pharmaceutical and biotechnology businesses that specialize in neurological illnesses, such as Parkinson's disease. These corporations use their experience in medicine discovery, marketing, and distribution to dominate the regional market and propel therapeutic innovation forward.

Patients in North America have access to a wide range of specialist healthcare services, such as movement disorder clinics, rehabilitation facilities, and multidisciplinary care teams. This comprehensive approach to Parkinson's disease care guarantees that patients receive individualized treatment strategies as well as holistic support throughout their disease journey.

The United States, in particular, devotes a considerable portion of its GDP to healthcare spending, demonstrating a strong commitment to disease prevention, treatment, and research. This significant investment creates a favorable environment for pharmaceutical companies and healthcare providers, adding to North America's supremacy in the Parkinson's Disease Treatment Market.

How do the Rapidly Aging Population and Growing Healthcare Expenditure in the Asia Pacific Region Contribute to the Rapid Expansion of the Parkinson's Disease Treatment Market?

The Asia Pacific region is estimated to exhibit the highest growth within the Parkinson's Disease Treatment Market during the forecast period. The Asia-Pacific area is undergoing a demographic change marked by a rapidly aging population. With rising life expectancy and changing lifestyle habits, the prevalence of age-related neurological illnesses like Parkinson's disease is increasing, creating a demand for effective treatment alternatives. Economic development and increased disposable incomes in Asia Pacific countries are driving up healthcare spending. Increased investment in healthcare infrastructure, research, and access to breakthrough therapies helps to grow the Parkinson's Disease Treatment Market in this region.

Emerging economies in Asia Pacific, including China, India, and South Korea, offer considerable growth potential for pharmaceutical businesses and healthcare providers. These countries are seeing fast urbanization, growing middle-class populations, and increased knowledge of neurological illnesses, which is driving demand for Parkinson's disease therapies. Governments in Asia Pacific are prioritizing healthcare reform and investing in disease management programs. Public health campaigns, drug subsidies, and attempts to increase healthcare access all help to drive the Parkinson's Disease Treatment Market forward by increasing patient access to treatment alternatives.

As Parkinson's disease becomes more well known in the Asia Pacific region, more sufferers seek medical attention and diagnosis for their symptoms. Improved disease recognition and diagnosis rates contribute to greater demand for Parkinson's disease therapies, which drives regional market growth. The Asia Pacific region has a huge and increasingly aging population, particularly in Japan, South Korea, and China. With aging being a prominent risk factor for Parkinson's disease, the growing elderly population provides a large patient pool for Parkinson's disease therapies, driving market expansion.

Competitive Landscape

The Parkinson's Disease Treatment Market is competitive, with significant pharmaceutical companies such as AbbVie Inc., GlaxoSmithKline plc, Novartis AG, and Teva Pharmaceutical Industries Ltd. These prominent players conduct considerable research and development initiatives to create new therapeutic methods and improve existing therapy alternatives. Strategic collaborations, partnerships, and acquisitions are common techniques for increasing market presence and improving product portfolios. Furthermore, competition in this market is driven by elements such as efficacy, safety, pricing, and market access tactics, all of which strive to suit the different demands of both patients and healthcare professionals.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the Parkinson's Disease Treatment Market include:

GSK, Merck, Novartis, Teva, Boehringer Ingelheim, Impax, Abbvie, Valeant Pharmaceuticals, Lundbeck, Sun Pharma, Wockhardt, Acadia, UCB.
Parkinson's Disease Treatment Market Latest Developments:
In March 2024, AbbVie Announced positive results from a Phase 2 clinical trial evaluating a new investigational drug for the treatment of Parkinson's disease. The drug showed promise in improving motor symptoms and potentially slowing disease progression.
In April 2024, Boehringer Ingelheim Presented data at a major neuroscience conference on a next-generation levodopa formulation with potentially sustained release properties. This could offer longer-lasting symptom control and reduce the need for frequent dosing.
In February 2024, Impax Laboratories Received FDA approval for a generic version of Rytary, a levodopa-carbidopa combination drug used for Parkinson's disease treatment. This can increase treatment options and potentially lower medication costs.

1 INTRODUCTION OF GLOBAL PARKINSON'S DISEASE TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY PATIENT CARE SETTING

5.1 Overview
5.2 Clinics
5.3 Hospitals

6 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospital Pharmacies
6.3 Retailer Pharmacies
6.4 Online Pharmacies

7 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY DRUG CLASS

7.1 Overview
7.2 Carbidopa/Levodopa
7.3 Dopamine Receptor Agonists
7.4 Mao Inhibitors
7.5 Comt Inhibitors
7.6 Anticholinergics
7.7 Other Drugs

8 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
8.6 Rest of the World
- 8.6.1 Latin America
- 8.6.2 Middle East and Africa

9 GLOBAL PARKINSON'S DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES

10.1 GSK
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merck
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Novartis
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Teva
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Boehringer Ingelheim
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Impax
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Abbvie
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Valeant Pharmaceuticals
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Lundbeck
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Sun Pharma
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 Wockhardt
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Acadia
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments
10.13 UCB
- 10.13.1 Overview
- 10.13.2 Financial Performance
- 10.13.3 Product Outlook
- 10.13.4 Key Developments